Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrgastro.2009.102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medicaid Policy and Hepatitis C Treatment Among Rural People Who Use Drugs.
Med Care
February 2025
Department of Medicine, Section of Infectious Diseases & Global Health, University of Chicago, Chicago, IL.
Background: Restrictive Medicaid policies regarding hepatitis C virus (HCV) treatment may exacerbate rural health care disparities for people who use drugs (PWUD). We assessed associations between Medicaid restrictions and HCV treatment among rural PWUD.
Methods: We compiled state-specific Medicaid treatment policies across 8 US rural sites in 10 states and merged these with participant survey data.
Understanding Barriers to Hepatitis C Antiviral Treatment in Low-Middle-Income Countries.
Healthcare (Basel)
December 2024
Center for Global Emergency Care, Johns Hopkins University, Baltimore, MD 21209, USA.
: Direct-acting antiviral agents (DAAs) have significantly reduced Hepatitis C Virus (HCV) transmission and improved health outcomes since their FDA approval in 2011. Despite these advances, over 70 million people remain untreated globally, with a disproportionately high burden in low- and middle-income countries (LMICs). : Through a structured search of open access informational sources and an informal peer-reviewed literature review, HCV treatment barriers were identified, compiled, and analyzed.
View Article and Find Full Text PDFDo oxidized low-density lipoproteins link to extra hepatic manifestations in chronic, non-cirrhotic HCV patients?
Metabol Open
March 2025
Hepatogastroenterology and Infectious Diseases Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Background: Tissue damage by viral hepatitis is a major cause of morbidity and mortality worldwide. Oxidation reactions and reactive oxygen species (ROS) transform proteins and lipids in plasma low-density lipoproteins (LDL) into the abnormal oxidized LDL (ox-LDL). Hepatitis C virus (HCV) infection induces oxidative/nitrosative stress from multiple sources, including the inducible nitric oxide synthase (iNOS), the mitochondrial electron transport chain, hepatocyte NAD(P)H oxidases (NOX enzymes), and inflammation.
View Article and Find Full Text PDFAnalysis of Repeat Hepatitis C Viremia After Sustained Virologic Response in a Large Cohort of U.S. Veterans.
Clin Infect Dis
January 2025
Veteran Affairs Portland Health Care System, Portland, OR, USA.
Background: Chronic hepatitis C virus (HCV) infection affects >1% of the U.S. population, higher among U.
View Article and Find Full Text PDFA randomized clinical study to evaluate the possible antifibrotic effect of zinc sulfate in chronic HCV patient receiving direct-acting anti-viral therapy.
Inflammopharmacology
January 2025
Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, El-Gharbia Government, Tanta, Egypt.
Objective: This study aimed to assess the potential antifibrotic impact of zinc sulfate in chronic Hepatitis C Virus (HCV) patients receiving direct-acting antiviral therapy.
Methods: This randomized controlled study included 50 chronic HCV-infected patients with fibrosis stage (F1 & F2). Participants were randomly assigned to two groups: Group 1 (Control group, n = 25) received standard direct-acting antiviral therapy for 3 months, while Group 2 (Zinc group, n = 25) received 50 mg/day of zinc sulfate in addition to the standard direct-acting antiviral therapy for the same duration.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!